| Hypertensive disease
Benicar vs Cleviprex
Side-by-side clinical, coverage, and cost comparison for hypertensive disease.Deep comparison between: Benicar vs Cleviprex with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCleviprex has a higher rate of injection site reactions vs Benicar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cleviprex but not Benicar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Benicar
Cleviprex
At A Glance
Oral
Daily
Angiotensin II receptor antagonist
IV infusion
Continuous infusion
Dihydropyridine CCB
Indications
- Hypertensive disease
- Hypertensive disease
Dosing
Hypertensive disease (Adults) Starting dose 20 mg once daily; may increase to 40 mg once daily after 2 weeks if further blood pressure reduction needed; oral.
Hypertensive disease (Pediatric, 6 years and older) 10 mg once daily for patients weighing 20 to <35 kg; 20 mg once daily for patients weighing >=35 kg; oral tablet or extemporaneous suspension.
Hypertensive disease Initiate IV infusion at 1-2 mg/hour; double dose at 90-second intervals initially, then increase by less than doubling every 5-10 minutes as goal blood pressure is approached; maintenance 4-6 mg/hour; maximum 16 mg/hour (up to 32 mg/hour for severe hypertension); lipid load limit 1000 mL or an average of 21 mg/hour per 24 hours.
Contraindications
- Co-administration of aliskiren in patients with diabetes
- Allergy to soybeans, soy products, eggs, or egg products
- Defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis accompanied by hyperlipidemia
- Severe aortic stenosis
Adverse Reactions
Most common (>1%) Dizziness
Postmarketing Asthenia, angioedema, anaphylactic reactions, vomiting, sprue-like enteropathy, hyperkalemia, rhabdomyolysis, acute renal failure, increased blood creatinine levels, alopecia, pruritus, urticaria
Most common Headache, nausea, vomiting, acute renal failure, atrial fibrillation
Serious Myocardial infarction, cardiac arrest, syncope, dyspnea
Postmarketing Increased blood triglycerides, ileus, hypersensitivity, hypotension, nausea, decreased oxygen saturation, reflex tachycardia
Pharmacology
Olmesartan medoxomil is a selective AT1 subtype angiotensin II receptor antagonist that blocks vasoconstrictor effects of angiotensin II by selectively blocking its binding to the AT1 receptor in vascular smooth muscle, acting independently of angiotensin II synthesis pathways.
Clevidipine is a dihydropyridine L-type calcium channel blocker that lowers blood pressure by inhibiting calcium influx in arterial smooth muscle, reducing systemic vascular resistance without affecting venous preload or cardiac filling pressure.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Benicar
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (1/12)
Cleviprex
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Benicar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Cleviprex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Benicar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Cleviprex
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Benicar.
No savings programs available for Cleviprex.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BenicarView full Benicar profile
CleviprexView full Cleviprex profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.